{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 140,
  "pageCount": 239,
  "prevPage": 139,
  "nextPage": 141,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Uses expert testimony to undermine company narrative regarding product success.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/140",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-140",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "They think Omnia's going to be a big thing. I just don't see it. Grossman even said on the earnings call that non-high frequency is utilized only 15% of the time.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b342-4e501063b26a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.88,
        "x": 0.06,
        "y": 0.52
      },
      "kind": "list",
      "text": "Two former Nevro territory managers independently stated that Nevro’s “not going to get more patients because of Omnia.” One is now at a key competitor and sees no impact from Omnia from his seat.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02365ce1-4673-4ff4-9d83-1c6f3afb8848",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.88,
        "x": 0.06,
        "y": 0.22
      },
      "kind": "list",
      "text": "The former sales executive stated that Omnia is “nothing new” and a dud, noting that Grossman has admitted that it’s still used as a high frequency device 85% of the time.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1219a140-a026-420d-b137-d92255dee0c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.96
      },
      "kind": "other",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": "source-note",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "661671b6-dadd-4eb0-a094-092230726f55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.88,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Another former executive, in a key sales role and now at a large competitor, offered an identical assessment that Omnia is a dud. In addition, two territory managers, both part of Nevro’s launch team and one now at a key competitor, concurred that they see no market impact.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7c2199f-fc7f-4542-86fd-a1bdc6c230ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.84,
        "x": 0.1,
        "y": 0.58
      },
      "kind": "quote",
      "text": "The market's not changing because of Omnia. The spinal cord stim market is what the spinal cord stim market is. You're not going to get more patients because of Omnia.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "279143e0-b1ee-48db-b3e1-37ada60d9d73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.84,
        "x": 0.1,
        "y": 0.68
      },
      "kind": "quote",
      "text": "I don't hear anything, from my team or anyone in my territory, that Nevro’s adoption with Omnia is now so much better. Some doctors are trying it out but I haven't heard anything revolutionary about it.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b03fe17-6d36-4e33-a5e8-f97e6bf4b61a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.84,
        "x": 0.1,
        "y": 0.31
      },
      "kind": "quote",
      "text": "They think Omnia’s going to be a big thing. I just don't see it. Grossman even said on the earnings call that non-high frequency is utilized only 15% of the time. There's nothing new...Nevro does not feel that a lot of these other waveforms are going to be utilized with Omnia.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fe7d402-5b67-4fa2-8e3d-fe8d87cbc01e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "They think Omnia's going to be a big thing. I just don't see it. Grossman even said on the earnings call that non-high frequency is utilized only 15% of the time. There's nothing new...Nevro does not feel that a lot of these other waveforms are going to be utilized with Omnia. It is rather to provide physicians with the perception that they have more options. The utilization of low-frequency and other waveforms besides high frequency will be very low, because one, a lot of Nevro's people don't know how to program those patients well because they've been utilizing the high-frequency algorithm and two, most of the time Senza is what people want. — Senior Nevro ex-sales executive; The market's not changing because of Omnia. The spinal cord stim market is what the spinal cord stim market is. You're not going to get more patients because of Omnia. Right now, you're just playing around in the same old market you've always been playing in, the same market I've been playing in my whole career, and the market's not really changing. — Former Nevro territory manager, one of the longest tenured SCS reps; I don't hear anything, from my team or anyone in my territory, that Nevro's adoption with Omnia is now so much better. Some doctors are trying it out but I haven't heard anything revolutionary about it. — Former Nevro territory manager now at a key competitor",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b342-53037e9c79a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.88,
        "x": 0.06,
        "y": 0.09
      },
      "kind": "title",
      "text": "10. The new Omnia stimulator, the centerpiece of Nevro’s turnaround hopes, is a Hail Mary and colossal flop",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b06788c7-4620-4453-b7a5-faaac4fec009",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be92508a-6b74-45e1-bfe9-26cef81e29fd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "81979259-12c2-496d-8a76-9d4a302a80a5",
      "evidence": "The use of bullet points to present multiple quotes and testimonials from experts.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "antagonist-introduction",
      "slug": null,
      "matchId": "0722a249-9fdb-4684-bf7d-b015ee933638",
      "evidence": "Uses former employees to frame the company's product as a failure.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}